Investigational drug · Phase 2
XNW29016
Also called: PARGi
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tumor, Solid.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "XNW29016"
First trial start
2025
Apr 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "XNW29016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tumor, Solid
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "XNW29016" as an intervention, largest first.
Evopoint Biosciences Inc.Industry
NCT06987500 · 132 participants (planned) · Start Apr 11, 2025 · Primary completion Feb 14, 2027
Drug: XNW29016; XNW29016 · For: Tumor, Solid
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- PARG inhibition elicits cytotoxicity by sequestering XRCC1 and other PAR-binding proteins into PAR-dependent nuclear condensates.
Dumoulin I, Lee BJ, Zhang C, et al. · Nat Commun 2026
- PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential.
Zhou X, Guo C, Fan Z, et al. · J Transl Med 2026
- PARG inhibition sequesters nuclear PAR-binding proteins, including XRCC1 and its partners, into nuclear condensates to elicit cytotoxicity.
Dumoulin I, Lee BJ, Zhang C, et al. · bioRxiv 2026
- Synergistic Cellular Toxicity from Inhibition of Poly(ADP-ribose) Glycohydrolase (PARG) and Ubiquitin-Specific Protease 1 (USP1).
Leonard SM, Pearson CR, Roos WP, et al. · Toxics 2026
- PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination.
Wang J, Dong Y, Lun W, et al. · NPJ Breast Cancer 2025
- PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer.
Ravindranathan R, Somuncu O, da Costa AABA, et al. · Proc Natl Acad Sci U S A 2024
Also in development for Tumor, Solid
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.